Oncology Nursing News

FDA OKs Subcutaneous Amivantamab Across All NSCLC Indications

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...
TCTMD

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Ferric carboxymaltose has become the first form of intravenous iron replacement to earn a US Food and Drug Administration indication for heart failure, the manufacturer announced today. Injectafer ...
Morningstar

FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)

INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...
Seeking Alpha

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...
Targeted Oncology

FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Medscape

International Approvals

Tocilizumab Approved for Rheumatoid Arthritis in Europe The European Commission has approved Roche's first-in-class therapeutic tocilizumab for the treatment of moderate-to-severe rheumatoid arthritis ...